2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes
Tamborlane WV, Polidori D, Argenti D, Di Prospero NA. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 649-655. PMID: 29271103, DOI: 10.1111/pedi.12626.Peer-Reviewed Original ResearchConceptsUrinary glucose excretionCanagliflozin 100Type 2 diabetesCanagliflozin 300T2D patientsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPharmacodynamics of canagliflozinSingle daily doseCotransporter 2 inhibitorsTreatment of adultsBody mass indexMaximum plasma concentrationPlasma glucose levelsDose-dependent increasePlasma concentration curveDaily doseGlucose excretionPediatric patientsMass indexPlasma concentrationsRenal thresholdGlucose levelsBody weightPatients
1987
Animal model of primary hyperparathyroidism
Jaeger P, Jones W, Kashgarian M, Baron R, Clemens T, Segre G, Hayslett J. Animal model of primary hyperparathyroidism. American Journal Of Physiology 1987, 252: e790-e798. PMID: 3591940, DOI: 10.1152/ajpendo.1987.252.6.e790.Peer-Reviewed Original ResearchConceptsTheoretical renal thresholdPrimary hyperparathyroidismPlasma levelsRenal thresholdAnimal modelsD plasma levelsPTH plasma levelsPlasma calcium levelsSynthetic parathyroid hormonePTH levelsDihydroxyvitamin DParathyroid hormoneParathyroidectomized animalsBovine PTHChronic hyperparathyroidismSustained elevationNormal limitsPlasma calciumHyperparathyroidismCalcium levelsOrgan systemsEpithelial functionControl valuesBasal levelsExperimental model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply